AN OBSERVATIONAL STUDY OF AVASTIN® (BEVACIZUMAB) IN COMBINATION WITH CHEMOTHERAPY FOR TREATMENT OF FIRST LINE METASTATIC COLORECTAL ADENOCARCINOMA (ACORN)

Study identification

• EU PAS number:
  EUPAS10344
• Study ID:
  10345
• Official title and acronym:
  AN OBSERVATIONAL STUDY OF AVASTIN® (BEVACIZUMAB) IN COMBINATION WITH CHEMOTHERAPY FOR TREATMENT OF FIRST LINE METASTATIC COLORECTAL ADENOCARCINOMA (ACORN)
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  STUDY OF BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY DESIGNED TO FOLLOW PATIENTS WITH METASTATIC COLORECTAL ADENOCARCINOMA
• Study status:
  Ongoing

Study timelines

Date when funding contract was signed

Actual: 01/09/2011

Study start date

Actual: 06/07/2012

Date of final study report

Planned: 31/08/2016

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Roche

Regulatory

• Was the study required by a regulatory body?:
  No